Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

42.12USD
4:00pm EDT
Price Change (% chg)

$-0.74 (-1.73%)
Prev Close
$42.86
Open
$42.75
Day's High
$42.87
Day's Low
$42.08
Volume
1,401,948
Avg. Vol
1,470,917
52-wk High
$43.27
52-wk Low
$32.70

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United... (more)

Overall

Beta: 0.64
Market Cap (Mil.): $64,373.09
Shares Outstanding (Mil.): 1,501.94
Dividend: 0.22
Yield (%): 2.05

Financials

  ABT.N Industry Sector
P/E (TTM): 30.79 35.82 36.29
EPS (TTM): 1.39 -- --
ROI: -- 18.85 18.13
ROE: -- 19.57 18.95
Search Stocks

Abbott beats profit estimate, infant formulas rebound

- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

16 Jul 2014

BRIEF-Abbott CEO says growth for nutritional products, pharmaceuticals "getting back on track"

July 16 - Abbott Laboratories : * CEO, in conference call, says growth for nutritional products, pharmaceuticals

16 Jul 2014

Sanofi held talks with Abbott, Mylan about mature drugs: document

PARIS - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

16 Jul 2014

Sanofi held talks with Abbott, Mylan on mature drugs -document

PARIS, July 16 - Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

Mylan to buy Abbott generics, cut taxes, in $5.3 billion deal

- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

14 Jul 2014

Abbott CEO says interested in acquiring more medical devices

- Abbott Laboratories <ABT.N) said on Monday it is interested in bolstering its line of medical devices, but it was becoming increasingly difficult to find appropriate and affordable products.

14 Jul 2014

UPDATE 2-Mylan to buy Abbott generics, cut taxes, in $5.3 bln deal

(Adds analyst comments, details of deal, company background, stock prices)

14 Jul 2014

Abbott CEO says interested in acquiring more medical devices

July 14 - Abbott Laboratories <ABT.N) said on Monday it is interested in bolstering its line of medical devices, but it was becoming increasingly difficult to find appropriate and affordable products.

14 Jul 2014

UPDATE 1-India caps price of 108 more medicines; drugmakers to take hit

* Move aimed towards making drugs more affordable in India

14 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $100.09 -2.21
Pfizer Inc. (PFE.N) $28.70 -0.56
Novartis AG (NOVN.VX) CHF79.55 -0.80
Merck & Co., Inc. (MRK.N) $56.74 -1.34
Sanofi SA (SASY.PA) €78.62 +1.73
AstraZeneca plc (AZN.L) 4,344.50p -13.00
GlaxoSmithKline plc (GSK.L) 1,436.50p +11.50
Eli Lilly and Co (LLY.N) $61.06 -1.56
Amgen, Inc. (AMGN.OQ) $127.39 -2.62
Medtronic, Inc. (MDT.N) $61.74 -0.84

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks